Haematology
Global

Haematology Experts

O Bairey

Professor
Institute of Hematology
Rabin Medical Center
Israel

Biography

Dr. O Bairey is affiliated to Institute of Hematology, Rabin Medical Center, where Dr. O Bairey is currently working as Professor. Dr. O Bairey has authored and co-authored several national and international publications and also working as a reviewer for reputed professional journals. Dr. O Bairey is having an active association with different societies and academies around the world. Dr. O Bairey made his mark in the scientific community with the contributions and widely recognition from honourable subject experts around the world. Dr. O Bairey has received several awards for the contributions to the scientific community. Dr. O Bairey major research interest involves Hematology and Medical Sciences.

Research Interest

Hematology and Medical Sciences

Publications

  • Pestalozzi BC, Francis P, Quinaux E, Dolci S, Azambuja E, Gelber RD, Viale G, Balil A, Andersson M, Nordenskjöld B, Gnant M, Gutierrez J, Láng I, Crown JP, Piccart-Gebhart M; BIG 02-98 Collaborative Group. Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial. Ann Oncol. 2008 Nov;19(11):1837-41.

  • Pestalozzi BC, Holmes E, de Azambuja E, Metzger-Filho O, Hogge L, Scullion M, Láng I, Wardley A, Lichinitser M, Sanchez RI, Müller V, Dodwell D, Gelber RD, Piccart-Gebhart MJ, Cameron D. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). Lancet Oncol. 2013 Mar;14(3):244-8.

  • Pestalozzi BC, Tausch C, Dedes KJ, Rochlitz C, Zimmermann S, von Moos R, Winterhalder R, Ruhstaller T, Mueller A, Buser K, Borner M, Novak U, Nussbaum CU, Seifert B, Bigler M, Bize V, Vilei SB, Rageth C, Aebi S; Swiss Group for Clinical Cancer Research (SAKK). Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10). BMC Cancer. 2017 Apr 13;17(1):265.

Global Experts from Israel

Global Experts in Subject